NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal (MTA)

TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (including a review of technology appraisal 143 and technology appraisal 233)

Matrix of consultees and commentators

Consultees		Commentators (no right to submit or appeal)		
Manufacturers/sponsors			General	
•	AbbVie (adalimumab)	•	Allied Health Professionals Federation	
•	Merck, Sharp & Dohme (golimumab, infliximab)	•	Board of Community Health Councils in Wales	
•	Pfizer (etanercept)	•	British National Formulary	
•	UCB Pharma (certolizumab pegol)	•	Care Quality Commission	
	,	•	Department of Health, Social Services	
Patient/carer groups			and Public Safety for Northern Ireland	
•	Action on Pain	•	Healthcare Improvement Scotland	
•	Afiya Trust	•	Medicines and Healthcare products	
•	Arthritic Association		Regulatory Agency	
•	Arthritis & Musculoskeletal Alliance	•	National Association of Primary Care	
	(ARMA)	•	National Pharmacy Association	
•	Arthritis Care	•	NHS Alliance	
•	BackCare	•	NHS Commercial Medicines Unit	
•	Black Health Agency	•	NHS Confederation	
•	Coalition of Ankylosing Spondylitis Patients	•	Scottish Medicines Consortium	
•	Disability Rights UK	Co	mparator manufacturer(s)	
•	Equalities National Council		None	
•	Leonard Cheshire Disability			
•	Muslim Council of Britain	Re	elevant research groups	
•	Muslim Health Network	•	Arthritis Research UK	
•	National Ankylosing Spondylitis	•	Chronic Pain Policy Coalition	
	Society	•	Cochrane Musculoskeletal Group	
•	Pain Concern	•	MRC Clinical Trials Unit	
•	Pain Relief Foundation	•	National Institute for Health Research	
•	Pain UK	•	Pain Relief Foundation	
•	South Asian Health Foundation	•	Society for Back Pain Research	
•	Specialised Healthcare Alliance		_	
		<u>Ass</u>	sessment Group	
<u>Pr</u>	ofessional groups	•	National Institute for Health Research	
•	Association of Surgeons of Great		Health Technology Assessment	
	Britain and Ireland		Programme	
•	Bone Research Society	•	NHS Centre for Reviews &	
			Dissemination and Centre for Health	

National Institute for Health and Care Excellence

TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (including a review of technology appraisal 143 and technology appraisal 233) Issue date: May 2014 Page 1 of 3

Consultees	Commentators (no right to submit or appeal)	
British Association of Occupational Therepiets	Economics –York	
 Therapists British Association of Surgical Oncology British Geriatrics Society British Health Professionals in Rheumatology British Institute of Musculoskeletal Medicine British Orthopaedic Association British Pain Society British Society for Rheumatology British Society of Rehabilitation Medicine Chartered Society of Physiotherapy College of Occupational Therapists Physiotherapy Pain Association Primary Care Rheumatology Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Surgeons Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine United Kingdom Clinical Pharmacy Association 	 Associated Guideline Groups National Clinical Guidelines Centre Associated Public Health Groups Public Health England Public Health Wales NHS Trust 	
Others • Department of Health		
NHS England		
NHS Oxfordshire CCG		
NHS Swale CCG		
Welsh Government		

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Care Excellence

TNF-alpha inhibitors for ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (including a review of technology appraisal 143 and technology appraisal 233) Issue date: May 2014 Page 2 of 3

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.